Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age

“…20,23,31,32 Measures of immunogenicity by rSBA after MenACWY-CRM have yielded much higher titers with prolonged persistence of antibodies. 33 However, the clinical relevance of these differences between serogroup responses are yet to be determined.…”

Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

“…Four clinical trials conducted in adolescents 11-18 y of age [13][14][15] and children 6-10 and 2-5 y of age 12,16 show a trend of high hSBA titers immediately post-vaccination, with an age-and serogroup-specific decline in titers up to 1 year, followed by relatively stable levels up to 5 y post-vaccination. In adolescents and children 2 y of age and older, the waning of bactericidal antibody titers over time was most pronounced for serogroup A, and, to a lesser extent, serogroup C.…”

“…[7][8][9][10] This review appraises data from 7 phase 3 and phase 4 studies, with the objective of providing an overview of antibody persistence following primary vaccination with MenACWY-CRM vaccine, and responses to booster doses of the vaccine. 9,10,[11][12][13][14][15][16][17][18][19] Only data pertaining to the recommended dose schedules of MenACWY-CRM in each age group is assessed here : a single dose in children 2-10 y of age, adolescents and adults; 4 doses at 2, 4, 6 and 12 months of age in infants; and 2 doses given to unvaccinated children between 7-23 months of age. All the studies included in this review were conducted in accordance with good clinical practice and International Conference on Harmonisation of Techniques for Requirements for Registration of Pharmaceuticals for Human Use guidelines, and were approved by Institutional Review Boards (IRBs) or Ethics Committees (ECs) in each country, as appropriate, prior to start of the study.…”

Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia

“…Reactions, n (%) 68 (40) 12 (32) 30 (45) 26 (39) chills, any 16 (9) 3 (8) 5 (8) 8 (12) chills, severe 1 (27) 18 (27) headache, severe 2 (1) 1 ( …”